1011 results about "Rectal carcinoma" patented technology

The present invention is directed to the compounds of Formula (IV) inhibitors of KRAS(G12D). The inhibitors described herein can be useful in the treatment of diseases or disorders associated with KRAS(G12D), such as Lung cancer, Pancreatic cancer, Colorectal cancer et al. In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting KRAS(G12D), methods of treating diseases or disorders associated with KRAS(G12D), and methods of synthesizing these compounds.

The invention relates to the technical field of assessment and early warning systems, and particularly discloses a rectal cancer operation risk assessment and early warning system based on multi-modal data fusion, which comprises a multi-modal data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic risk assessment module, an intelligent early warning module and a system self-checking module. By integrating multi-modal data and dynamically allocating weights, real-time risk updating in the whole operation period is achieved, the comprehensiveness, timeliness and precision of risk assessment are comprehensively improved by combining the grading early warning function, the autonomous detection calibration function and the risk tracing and countermeasure matching function, long-term reliable operation of the system is guaranteed, powerful support is provided for clinical decision making, and the risk assessment method is suitable for clinical decision making. The surgical risk and the complication occurrence rate are effectively reduced.

The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to lung cancer, pancreatic cancer, colorectal cancer, and solid tumors. In particular, the disclosure provides compounds of Formula (I):, and pharmaceutically acceptable salts thereof, wherein the substituents are as described.

The invention discloses an interpretability analysis and decision sharing verification method and system for a rectal cancer prognosis model, and relates to the field of medical artificial intelligence interpretability. The method comprises the following steps: carrying out gradient weighting class activation mapping analysis on a prognosis model to generate an image thermodynamic diagram; calculating the contribution degree of the multi-modal features by using an SHAP interpreter; an integrated visual interface is constructed, and patient data, model prediction and the explanation result are presented to a doctor together; the doctor performs independent risk assessment based on the interface information; finally, decisions of doctors and the model are compared, and model auxiliary efficiency is evaluated. Through a doctor-model decision sharing verification mechanism which is explained and innovated in a multi-level mode, the transparency and clinical credibility of the complex AI prognosis model are remarkably improved, the value of time sequence data in dynamic risk assessment can be verified, and clinical landing application of the AI model is powerfully promoted.

Disclosed herein is use of a combination of Compound (A) (azenosertib), or a pharmaceutically acceptable salt thereof, and a KRAS G12C inhibitor, such as sotorasib or adagrasib, or a pharmaceutically acceptable salt thereof, for treating a disease or condition, such as a colorectal, pancreatic and / or non-small cell lung cancer.

The invention discloses application of MUC12 gene in preparation of drugs for reducing rectal cancer liver metastasis, and belongs to the technical field of medical biology. According to the invention, the clear relation between colorectal cancer liver metastasis and fructose metabolism reprogramming is revealed from a molecular mechanism for the first time. The invention provides a brand-new therapeutic target and strategy by determining the brand-new transfer promoting factor MUC12 and the mediated fructose metabolism regulation effect thereof. Different from the traditional therapy only aiming at the strategies of tumor cell proliferation, blood supply and the like, the method disclosed by the invention intervenes aiming at a tumor nutrition metabolic pathway, and can weaken the metabolic adaptation and proliferation capacity of metastatic tumor cells in the liver more specifically. Experimental results show that the functions of targeted inhibition of MUC12 or downstream fructose metabolism key enzymes KHK and ALDOB thereof can significantly reduce the invasion and metastasis ability of tumor cells, and at the same time, normal growth of primary tumors cannot be significantly affected.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention provides Eubacterium mucilaginosus E11405 and an application thereof. The invention provides Eubacterium mucus E11405, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the Eubacterium mucus E11405 is CGMCC No.31231. The invention further provides a preparation method of the Eubacterium mucus E11405. The inventor of the application studies the effect and mechanism of the Eubacterium mucus E11405 in relieving the mouse colorectal cancer, and the result shows that the Eubacterium mucus E11405 has a remarkable relieving effect on the mouse colorectal cancer, and can be used as a probiotic preparation for relieving the colorectal cancer. The Eubacterium mucilaginosus E11405 provides a new strategy for prevention and treatment of colorectal cancer-based digestive tract tumors, has potential clinical application prospects, and is expected to become an effective medicine for treating colorectal cancer-based digestive tract tumors.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The invention provides a rectal cancer patient management method and system based on postoperative rehabilitation data analysis, and relates to the field of postoperative rehabilitation management. And executing cross-scene associated feature anomaly recognition to extract a sensitive feature variable set as observation input of the hidden Markov model, driving a rehabilitation stage transition probability to calculate and output a state anomaly feature combination, comparing and positioning a real-time rehabilitation state, calculating and outputting a dynamic rehabilitation stage switching time window, and sending the dynamic rehabilitation stage switching time window to a medical end screen display. The technical problems in the prior art that rehabilitation stage division is extensive, rehabilitation stage switching prediction precision of individual users is insufficient, and rehabilitation management suitability is affected are solved. The technical effects of eliminating the rehabilitation stage division lag effect, performing rehabilitation stage switching accurate prediction and providing high-reliability time sequence feature support for rehabilitation management are achieved.

The invention discloses an eRNA molecular marker for auxiliary diagnosis of colorectal cancer and application of the eRNA molecular marker, and is characterized in that the eRNA molecular marker is eRNA eCOL4A1, and the nucleotide sequence of the eRNA molecular marker is shown as SEQ ID NO.1. The invention further provides application of the eRNA molecular marker in preparation of a kit for auxiliary diagnosis of colorectal cancer, and the eRNA molecular marker comprises a fluorescent quantitative PCR specific amplification primer for detecting the eRNA eCOL4A1 in a plasma sample, the nucleotide sequence of the upstream primer is 5 '-GGGCAGTGATGTGTAGATGAGTT-3', the nucleotide sequence of the downstream primer is 5 '-TGAACATCACATGGAGC-3', and the kit has the advantages that absolute quantitative detection of target molecules and early screening and identification of colorectal cancer can be rapidly and accurately completed only by a small amount of samples, and the kit is high in sensitivity, high in accuracy and rapid in detection.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The invention discloses a rectal cancer medical image lesion segmentation method and device based on deep learning, and aims to solve the problem that in the prior art, only a medical image is used as a single input mode, and potential semantic association among multi-mode data is neglected, so that the segmentation effect is poor. The method comprises the following steps: acquiring a to-be-detected rectal cancer medical image focus image and corresponding clinical text information, and inputting the two images into a segmentation model for processing; the clinical text information is processed through a text multi-scale feature extraction module, and target text multi-scale features are generated; encoding the text features and the medical image by using a feature encoder, and outputting target text image fusion encoding features; inputting the fusion coding feature into a scale attention module, and outputting a target text image fusion attention feature; processing the fusion attention feature and the fusion coding feature through a feature decoder to obtain a target text image decoding feature; and finally, segmenting the decoding features by using a segmentation head, and outputting a final target segmentation result.

Disclosed herein are methods and compositions for quantifying distinct prognostic and predictive contributions of tumor epithelium vs. tumor microenvironment in colorectal cancer to optimize therapy.

The present application relates to the technical field of small molecule drugs, in particular to a isoquinoline drug and its application in improving or treating digestive tract tumors, and aims to provide a compound, a pharmaceutical composition containing the compound and its application in treating colorectal cancer and gastric cancer, and provides a 3,13-position substituted berberine derivative, the drug itself has less toxicity and does not affect the growth of normal human cells, and has a good application prospect in the development of novel antitumor drugs, especially in the development of anti-digestive tract tumor drugs.

The invention discloses a rectal cancer tumor T stage differentiation labeling method based on an enhanced CT image, and relates to the field of medical image data processing, and the method comprises the following steps: a standardized manual labeling module which is used for constructing three-dimensional pixel-level labeling data of a rectal cancer tumor T stage according to a medical image and a pathological stage standard; the data set construction module is used for uniformly storing and organizing the original CT image, the annotation mask file and the matched label description document to form a structured data set which can be used for modeling; according to the rectal cancer tumor T-stage differentiation labeling method based on the enhanced CT image, a high-quality and standardized three-dimensional T-stage labeling data set is constructed, a three-dimensional pixel-level stage labeling process for the rectal cancer enhanced CT image is provided based on the AJCC eighth version tumor stage standard, the labeling content covers tumor focuses and normal intestinal wall structures around the tumor focuses, and the three-dimensional T-stage labeling data set is established. A plurality of high-annuity imaging department doctors perform independent blind marking, expert re-checking, quality rating and the like.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention belongs to the technical field of biological medicines, and particularly discloses an alkynyl pyrimidine derivative as well as a preparation method and application thereof. The structure of the alkynyl pyrimidine derivative is shown as a formula I. The novel alkynyl pyrimidine derivative capable of efficiently inhibiting the LSD1 activity is provided, the preparation process is simple and easy to implement, the good effect of resisting colorectal cancer cell proliferation is shown on the animal level, and safe and effective candidate drug molecules are provided for targeted therapy of colorectal cancer.

Disclosed herein are systems, methods, and compositions for treating a subject diagnosed with, or suffering from cancer. In some embodiments, the method comprises determining whether a tumor sample from the subject includes a cytotoxic gene signature, and treating the subject based on the determination. In some embodiments, the subject has or is suspected of having a loss of heterozygosity in human leukocyte antigen (HLA) class I genes. In some embodiments, the therapy comprises one or more checkpoint inhibitors. In some embodiments, the cancer is colorectal, uterine, stomach, lung, skin, head or neck, or non-small cell lung carcinoma.

The invention discloses a phosphorylated peptidomimetic compound and a medical application thereof. The invention provides a phosphorylated peptidomimetic compound with a novel structure. Activity research shows that the phosphorylated peptidomimetic compound has excellent Cbl-b inhibitory activity and is an effective Cbl-b inhibitor. Technicians in the field know that Cbl-b overexpression can inhibit T cell immune response, and inhibition of Cbl-b can activate killing of an immune system on tumor cells. Therefore, the phosphorylated peptidomimetic compound or pharmaceutically acceptable salts and solvates thereof provided by the invention can be developed and prepared into drugs for treating diseases (such as non-small cell lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer and other tumors) treated or relieved by inhibiting Cbl-b (such as non-small cell lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer and the like) the medicine prospect is promising.

The invention discloses a longitudinal CT image-assisted rectal cancer neoadjuvant radiotherapy and chemotherapy treatment reaction evaluation device, which comprises a focus area segmentation module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module and a rectum focus area detection module, obtaining a standardized three-dimensional tumor area; a feature fusion module extracts deep learning features of a focus area after segmentation at two time points before neoadjuvant radiotherapy and chemotherapy and before an operation from the three-dimensional tumor area, and performs weighted fusion on the deep learning features at the two time points through a dynamic attention weight layer to obtain longitudinal comprehensive features representing tumor treatment response changes; and the prediction module fuses the longitudinal comprehensive characteristics and clinical baseline data to construct a multi-modal prediction model, and outputs a treatment response prediction result of the rectal cancer patient on neoadjuvant chemoradiotherapy, so that the prediction accuracy of pathological complete remission of the rectal cancer patient can be improved, and the prognosis of the patient and the utilization efficiency of medical resources can be improved.

The present disclosure is directed to methods of treating colorectal cancer in a subject in need thereof with a menin-MLL inhibitor, including Compound A:Methods for dosing Compound A for various indications are also provided by the present disclosure.

The invention discloses a novel colorectal cancer organoid culture method, which obviously improves the activity of primary cells (more than or equal to 90%) and the forming efficiency of the organoid (the success rate is more than 95%) through alcohol gradient cleaning, collagenase-hyaluronidase combined digestion and stent-free culture technologies. The improved culture medium takes R-Spondin1 as a core, nicotinamide and a small-molecule inhibitor are combined, and long-term amplification of organoids (passage is more than or equal to 10 times) is supported. The method is suitable for individualized drug screening, tumor microenvironment simulation and drug resistance mechanism research, has the advantages of high efficiency, stability and low cost, and provides a reliable model for precise medical treatment of colorectal cancer.

The invention discloses a marker for early colorectal neoplastic lesion diagnosis and application, and belongs to the technical field of biological medicine. Aiming at the problems of low colonoscopy coincidence rate of colorectal cancer patients at present and limited sensitivity and specificity of existing biomarker diagnosis, LncRNA sequencing research is combined with expanded sample verification to obtain high-specificity and high-sensitivity LncRNA which is highly related to colorectal neoplastic lesions (including adenoma and colorectal cancer), the LncRNA is specifically LOC401585, and the LncRNA has the advantages of high specificity, high sensitivity, high specificity and high sensitivity and can be used for detecting colorectal neoplastic lesions (including adenoma and colorectal cancer). The diagnosis efficacy AUC of the LOC401585 on the adenoma and the colorectal cancer is 0.952 and 0.876 respectively. Therefore, the blood LOC401585 marker can be used for auxiliary diagnosis of colorectal neoplastic lesions, and provides data support for finding novel small molecule drugs with potential treatment value.

The invention belongs to the field of biotechnology and medical technology, and discloses application of tumor-associated macrophages with high expression of SLC16A10 in prognosis diagnosis and treatment of colorectal cancer. According to the invention, colorectal cancer single-cell transcriptome sequencing data analysis before and after anti-PD-1 treatment is carried out in the earlier stage; the tumor-associated macrophage subgroup with high expression of the SLC16A10 is enriched in a response group after colorectal cancer anti-PD-1 treatment, and the prognosis of a colorectal cancer patient with high expression of the SLC16A10 is good. Knock-down of the SLC16A10 leads to reduction of expression of the macrophage M1 type marker, and activation and toxicity of co-cultured T cells are reduced. The SLC16A10 promotes T cell activation and weakens immunosuppression on T cells, so that colorectal cancer anti-PD-1 treatment response is caused. The research explains the influence and mechanism of the macrophage SLC16A10 on colorectal cancer anti-PD-1 treatment, and provides a new strategy and theoretical basis for immunotherapy of colorectal cancer.

The invention discloses a colorectal cancer metabolism-related prognosis model construction method based on multiple omics. By integrating multiple omics data, the defect is overcome, a new view angle and method are provided, the accuracy and practicability of the prognosis model are effectively improved, and the blank in the prior art is filled. Meanwhile, the method provided by the invention is not only suitable for prognosis prediction of colorectal cancer patients, but also can be popularized and applied to other types of cancers. As the metabolism-related gene plays an important role in various cancers, the technical scheme provided by the invention has relatively high universality and popularization value, and can provide reference for prognosis prediction and personalized treatment of other cancers. Finally, the prognosis model provided by the invention can be used as a clinical decision support tool to help doctors to make more scientific and accurate decisions in diagnosis and treatment processes. Through early recognition of high-risk patients and implementation of targeted intervention measures, prognosis of the patients can be significantly improved, and the risk of relapse and metastasis can be reduced.

The invention discloses an application of 2, 3-dihydroxybenzoic acid in preparation of an antitumor drug. Researches find that 2, 3-dihydroxybenzoic acid can inhibit proliferation, migration and invasion of colorectal cancer cells in vitro and promote cell cycle arrest and cell apoptosis, and 2, 3-dihydroxybenzoic acid can inhibit growth of mouse transplanted tumors in vivo and promote cell apoptosis; the 2, 3-dihydroxybenzoic acid has a remarkable treatment effect on mouse colon cancer and can improve the immunotherapy effect; moreover, the 2, 3-dihydroxybenzoic acid small molecule substance, as an inhibitor of fatty acid synthase (FASN), plays an important role in inhibiting colorectum.

The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g., carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.

The invention discloses a colorectal cancer Septin9 gene methylation detection kit based on a graded anchoring probe, and belongs to the technical field of molecular diagnosis. The graded anchoring probe is composed of a specific capture probe (F1), a precise anchoring probe (R1), a synergistic blocking probe (F2 / R2) and a short chain complementary sequence (S1) which are Septin9 methylation specific probes and can be fixed in a conical pore channel of a nuclear track membrane in a graded manner to form a capture-anchoring-blocking functional chain; during application, a general accumulation body is formed by combining with a Septin9 methylation target, a nuclear track membrane pore channel is blocked, current drop is caused, and detection is realized. Through cooperation of the probe, the nuclear track membrane and the electrochemistry, the problems of insufficient sensitivity, poor stability and poor specificity of traditional detection are solved, and the kit is suitable for ultra-early diagnosis of colorectal cancer.